Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.3.1.20 - diacylglycerol O-acyltransferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adrenocortical Carcinoma
Identification of novel lipid metabolic biomarkers associated with poor adrenocortical carcinoma prognosis using integrated bioinformatics.
Alopecia
Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice.
Pharmacological inhibition of DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia is restricted to the mouse.
Retinol Esterification by DGAT1 Is Essential for Retinoid Homeostasis in Murine Skin.
Arthritis
Arthritis severity locus Cia4 is an early regulator of IL-6, IL-1?, and NF-?B activators' expression in pristane-induced arthritis.
Atherosclerosis
Intestine-specific DGAT1 deficiency improves atherosclerosis in apolipoprotein E knockout mice by reducing systemic cholesterol burden.
Lack of acyl-CoA:diacylglycerol acyltransferase 1 reduces intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E knockout mice.
Potential therapeutics for obesity and atherosclerosis: inhibitors of neutral lipid metabolism from microorganisms.
Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium.
Brain Neoplasms
DGAT1 protects tumor from lipotoxicity, emerging as a promising metabolic target for cancer therapy.
Carcinoma, Hepatocellular
CTRP12 inhibits triglyceride synthesis and export in hepatocytes by suppressing HNF-4? and DGAT2 expression.
Dgat2 reduces hepatocellular carcinoma malignancy via downregulation of cell cycle-related gene expression.
Diacylglycerol acyltransferase-2 (DGAT2) and monoacylglycerol acyltransferase-2 (MGAT2) interact to promote triacylglycerol synthesis.
Overexpression of human diacylglycerol acyltransferase 1, acyl-coa:cholesterol acyltransferase 1, or acyl-CoA:cholesterol acyltransferase 2 stimulates secretion of apolipoprotein B-containing lipoproteins in McA-RH7777 cells.
Sesquiterpenoids Isolated from the Flower Buds of Tussilago farfara L. Inhibit Diacylglycerol Acyltransferase.
The ménage à trois of autophagy, lipid droplets and liver disease.
The Role of Bone Morphogenetic Protein Signaling in Non-Alcoholic Fatty Liver Disease.
Urokinase-type plasminogen activator (uPA) stimulates triglyceride synthesis in Huh7 hepatoma cells via p38-dependent upregulation of DGAT2.
Cardiomegaly
Reduction of Rat Cardiac Hypertrophy by Osthol is Related to Regulation of Cardiac Oxidative Stress and Lipid Metabolism.
Cardiomyopathies
A murine model of isolated cardiac steatosis leads to cardiomyopathy.
Diacylglycerol acyl transferase 1 overexpression detoxifies cardiac lipids in PPAR? transgenic mice.
Inborn errors of cytoplasmic triglyceride metabolism.
ceramidase deficiency
Endogenous levels of 1-O-acylceramides increase upon acidic ceramidase deficiency and decrease due to loss of Dgat1 in a tissue-dependent manner.
Charcot-Marie-Tooth Disease
DGAT2 Mutation in a Family with Autosomal Dominant Early-Onset Axonal Charcot-Marie-Tooth Disease.
Citrullinemia
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
coagulation factor xia deficiency
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
COVID-19
Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators.
Dehydration
Stability of diacylglycerol acyltransferase in dehydrated bovine muscle tissue.
The important role of epidermal triacylglycerol metabolism for maintenance of the skin permeability barrier function.
Dermatitis, Phototoxic
Successful Strategies for Mitigation of a Preclinical Signal for Phototoxicity in a DGAT1 Inhibitor.
The DGAT1 inhibitor pradigastat does not induce photosensitivity in healthy human subjects: a randomized controlled trial using three defined sunlight exposure conditions.
Diabetes Mellitus
DGAT: novel therapeutic target for obesity and type 2 diabetes mellitus.
Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial.
RNA interference-mediated knockdown of DGAT1 decreases triglyceride content of bovine mammary epithelial cell line.
Sesquiterpenoids Isolated from the Flower Buds of Tussilago farfara L. Inhibit Diacylglycerol Acyltransferase.
Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance.
Diabetes Mellitus, Type 2
A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism.
Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor.
DGAT: novel therapeutic target for obesity and type 2 diabetes mellitus.
Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial.
Diacylglycerol acyltransferase-inhibitory compounds from Erythrina senegalensis.
Effects of Morus root bark extract and active constituents on blood lipids in hyperlipidemia rats.
Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: Lessons from mice lacking DGAT1.
Inhibition of diacylglycerol acyltransferase by alkamides isolated from the fruits of Piper longum and Piper nigrum.
Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice.
Inhibitory activity of diacylglycerol acyltransferase by glabrol isolated from the roots of licorice.
Isolation of Diacyl Glycerol Acyl Transferase (DGAT) Inhibitors from Pachydictyon coriaceum.
Prolonged silencing of diacylglycerol acyltransferase-1 induces a dedifferentiated phenotype in human liver cells.
Proof of mechanism for the DGAT1 inhibitor AZD7687: Results from a first-time-in-human single dose study.
Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases.
Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance.
diacylglycerol o-acyltransferase deficiency
A Fluorescence-based Assay for Characterization and Quantification of Lipid Droplet Formation in Human Intestinal Organoids.
Acyl-CoA:Diacylglycerol Acyltransferase 1 Expression Level in the Hematopoietic Compartment Impacts Inflammation in the Vascular Plaques of Atherosclerotic Mice.
Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations.
Deficiency of acyl coenzyme a:diacylglycerol acyltransferase 1 increases leptin sensitivity in murine obesity models.
DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle.
DGAT1 deficiency disrupts lysosome function in enterocytes during dietary fat absorption.
DGAT1 mutations leading to delayed chronic diarrhoea: a case report.
DGAT1 promoter polymorphism associated with alterations in body mass index, high density lipoprotein levels and blood pressure in Turkish women.
Diacylglycerol acyltransferase-1 (DGAT1) inhibition perturbs postprandial gut hormone release.
Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin.
Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: Lessons from mice lacking DGAT1.
Hepatocyte Deletion of Triglyceride-Synthesis Enzyme Acyl CoA: Diacylglycerol Acyltransferase 2 Reduces Steatosis Without Increasing Inflammation or Fibrosis in Mice.
Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1.
Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice.
Intestinal DGAT1 deficiency markedly reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying.
Intestinal failure and aberrant lipid metabolism in patients with DGAT1 deficiency.
Intestine-specific DGAT1 deficiency improves atherosclerosis in apolipoprotein E knockout mice by reducing systemic cholesterol burden.
Lack of acyl-CoA:diacylglycerol acyltransferase 1 reduces intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E knockout mice.
Leptin modulates the effects of acyl CoA:diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands.
Novel role of a triglyceride-synthesizing enzyme: DGAT1 at the crossroad between triglyceride and cholesterol metabolism.
Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1.
Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat.
Palmitic Acid and DGAT1 Deficiency Enhance Osteoclastogenesis while Oleic Acid-Induced Triglyceride Formation Prevents it.
Retinol Esterification by DGAT1 Is Essential for Retinoid Homeostasis in Murine Skin.
Role of adipocyte-derived factors in enhancing insulin signaling in skeletal muscle and white adipose tissue of mice lacking Acyl CoA:diacylglycerol acyltransferase 1.
Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids.
Sterol and diacylglycerol acyltransferase deficiency triggers fatty acid mediated cell death.
Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance.
Dwarfism
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
Dyslipidemias
A murine model of isolated cardiac steatosis leads to cardiomyopathy.
A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism.
A simple homogeneous scintillation proximity assay for acyl-coenzyme A:diacylglycerol acyltransferase.
DGAT2 Inhibition Alters Aspects of Triglyceride Metabolism in Rodents but Not in Non-human Primates.
Discovery of Orally Active Carboxylic Acid Derivatives of 2-Phenyl-5-trifluoromethyloxazole-4-carboxamide as Potent Diacylglycerol Acyltransferase-1 Inhibitors for the Potential Treatment of Obesity and Diabetes.
Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia.
Elevated metabolic rate and skeletal muscle oxidative metabolism contribute to the reduced susceptibility of NF-?B p50 null mice to obesity.
Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.
Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients.
Dystocia
Deciphering signature of selection affecting beef quality traits in Angus cattle.
Encephalomyelitis
DGAT1 inhibits retinol-dependent regulatory T cell formation and mediates autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
DGAT1 inhibits retinol-dependent regulatory T cell formation and mediates autoimmune encephalomyelitis.
Escherichia coli Infections
Dysregulation of Lipid Metabolism in Mkp-1 Deficient Mice during Gram-Negative Sepsis.
Factor XI Deficiency
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
Farber Lipogranulomatosis
Endogenous levels of 1-O-acylceramides increase upon acidic ceramidase deficiency and decrease due to loss of Dgat1 in a tissue-dependent manner.
Fatty Liver
Betaine attenuates chronic alcohol?induced fatty liver by broadly regulating hepatic lipid metabolism.
Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets.
Dietary fat composition influences tissue lipid profile and gene expression in Fischer-344 rats.
Hepatic triacylglycerol synthesis during a period of fatty liver development in sheep.
Hepatic triacylglycerol synthesizing activity during progression of alcoholic liver injury in the baboon.
Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease.
JTP-103237, a monoacylglycerol acyltransferase inhibitor, prevents fatty liver and suppresses both triglyceride synthesis and de novo lipogenesis.
Low abundance of mitofusin 2 in dairy cows with moderate fatty liver is associated with alterations in hepatic lipid metabolism.
Mangiferin treatment inhibits hepatic expression of acyl-coenzyme A:diacylglycerol acyltransferase-2 in fructose-fed spontaneously hypertensive rats: a link to amelioration of fatty liver.
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Osthole improves fat milk-induced fatty liver in rats: modulation of hepatic PPAR-alpha/gamma-mediated lipogenic gene expression.
Osthole regulates enzyme protein expression of CYP7A1 and DGAT2 via activation of PPARalpha/gamma in fat milk-induced fatty liver rats.
Perilipin 5 promotes hepatic steatosis in dairy cows through increasing lipid synthesis and decreasing very low density lipoprotein assembly.
Recent advances in pharmacotherapy for hypertriglyceridemia.
Rescue of Mtp siRNA-induced hepatic steatosis by DGAT2 siRNA silencing.
Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation.
Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids.
The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans.
The ménage à trois of autophagy, lipid droplets and liver disease.
Treatment of rats with Jiangzhi Capsule improves liquid fructose-induced fatty liver: modulation of hepatic expression of SREBP-1c and DGAT-2.
[6]-gingerol dampens hepatic steatosis and inflammation in experimental nonalcoholic steatohepatitis.
Fatty Liver, Alcoholic
Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease.
Genetic Diseases, Inborn
Deciphering signature of selection affecting beef quality traits in Angus cattle.
Glioblastoma
DGAT1 protects tumor from lipotoxicity, emerging as a promising metabolic target for cancer therapy.
Targeting DGAT1 Ameliorates Glioblastoma by Increasing Fat Catabolism and Oxidative Stress.
Glucose Intolerance
Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin.
Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: Lessons from mice lacking DGAT1.
Exposure to high fructose corn syrup during adolescence in the mouse alters hepatic metabolism and the microbiome in a sex-specific manner.
Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1.
The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment.
The triglyceride synthesis enzymes DGAT1 and DGAT2 have distinct and overlapping functions in adipocytes.
Heart Failure
Cardiomyocyte-specific loss of diacylglycerol acyltransferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failure.
Hepatitis B
Expression of genes involved in lipogenesis is not increased in patients with HCV genotype 3 in human liver.
Hepatitis C
Current Status of the Research and Development of Diacylglycerol O-Acyltransferase 1 (DGAT1) Inhibitors.
Diacylglycerol acyltransferase-1: a critical host factor for hepatitis C virus assembly and potential new drug target.
Diacylglycerol glycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core.
Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1.
Hepatitis C virus entry is impaired by claudin-1 downregulation in diacylglycerol acyltransferase-1-deficient cells.
Suppression of Hepatitis C Virus Genome Replication and Particle Production by a Novel Diacylglycerol Acyltransferases Inhibitor.
Hepatoblastoma
Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells.
Hernia, Umbilical
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
Hypercholesterolemia
Novel role of a triglyceride-synthesizing enzyme: DGAT1 at the crossroad between triglyceride and cholesterol metabolism.
Hyperglycemia
A murine model of isolated cardiac steatosis leads to cardiomyopathy.
Hyperlipidemias
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
Hepatic triacylglycerol synthesizing activity during progression of alcoholic liver injury in the baboon.
In vivo efficacy of acyl CoA: Diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia.
Mechanistic Characterization of Long Residence Time Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2).
Pharmacological inhibition of diacylglycerol acyltransferase 1 reduces body weight gain, hyperlipidemia, and hepatic steatosis in db/db mice.
Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies.
Hyperlipoproteinemia Type I
Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor.
Effect of Pradigastat, a Diacylglycerol Acyltransferase 1 Inhibitor, on the QTcF Interval in Humans.
Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor.
Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome.
Evaluation of food effect on the oral bioavailability of pradigastat, a diacylglycerol acyltransferase 1 inhibitor.
Pradigastat disposition in humans: in vivo and in vitro investigations.
Successful Strategies for Mitigation of a Preclinical Signal for Phototoxicity in a DGAT1 Inhibitor.
Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy.
Hypertriglyceridemia
Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster.
Identification of a botanical inhibitor of intestinal diacylglyceride acyltransferase 1 activity via in vitro screening and a parallel, randomized, blinded, placebo-controlled clinical trial.
Identification of diacylglycerol acyltransferase inhibitors from Rosa centifolia petals.
Inborn errors of cytoplasmic triglyceride metabolism.
Knockdown of Acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice.
Up-regulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome.
Hypothyroidism
Comparison of triacylglycerol synthesis in rat brown and white adipocytes. Effects of hypothyroidism and streptozotocin-diabetes on enzyme activities and metabolic fluxes.
Ichthyosis
Inborn errors of cytoplasmic triglyceride metabolism.
Infections
A novel bifunctional wax ester synthase/acyl-CoA:diacylglycerol acyltransferase mediates wax ester and triacylglycerol biosynthesis in Acinetobacter calcoaceticus ADP1.
Diacylglycerol glycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core.
Dysregulation of Lipid Metabolism in Mkp-1 Deficient Mice during Gram-Negative Sepsis.
Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1.
Necrosis Driven Triglyceride Synthesis Primes Macrophages for Inflammation During Mycobacterium tuberculosis Infection.
Infertility
On the Role of DGAT1 in Seed Glycerolipid Metabolic Network and Critical Stages of Plant Development in Arabidopsis.
Insulin Resistance
A novel diacylglycerol acyltransferase (DGAT2) is decreased in human psoriatic skin and increased in diabetic mice.
Abrogating Monoacylglycerol Acyltransferase Activity in Liver Improves Glucose Tolerance and Hepatic Insulin Signaling in Obese Mice.
Analysis of Differentially Expressed Genes in Gastrocnemius Muscle between DGAT1 Transgenic Mice and Wild-Type Mice.
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
Beyond Triglyceride Synthesis: The Dynamic Functional Roles of MGAT and DGAT Enzymes in Energy Metabolism.
Bioactive Compounds from Lemon (Citrus limon) Extract Overcome TNF-?-Induced Insulin Resistance in Cultured Adipocytes.
Bromodomain-containing protein 4 regulates a cascade of lipid-accumulation-related genes at the transcriptional level in the 3T3-L1 white adipocyte-like cell line.
Decreased lipogenesis-promoting factors in adipose tissue in postmenopausal women with overweight on a Paleolithic-type diet.
Deficiency of acyl coenzyme a:diacylglycerol acyltransferase 1 increases leptin sensitivity in murine obesity models.
DGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammation.
Discovery of a novel class of diacylglycerol acyltransferase 2 inhibitors with a 1H-pyrrolo[2,3-b]pyridine core.
Discovery of Orally Active Carboxylic Acid Derivatives of 2-Phenyl-5-trifluoromethyloxazole-4-carboxamide as Potent Diacylglycerol Acyltransferase-1 Inhibitors for the Potential Treatment of Obesity and Diabetes.
Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.
Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver.
Dissociation of obesity and impaired glucose disposal in mice overexpressing acyl coenzyme a:diacylglycerol acyltransferase 1 in white adipose tissue.
Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin.
Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: Lessons from mice lacking DGAT1.
Expression of DGAT2 in white adipose tissue is regulated by central leptin action.
Glycerolipid acyltransferases in triglyceride metabolism and energy homeostasis-potential as drug targets.
Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2.
Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia.
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
Identification and validation of a selective small molecule inhibitor targeting the diacylglycerol acyltransferase 2 activity.
Improved glucose tolerance in acyl CoA:diacylglycerol acyltransferase 1-null mice is dependent on diet.
In vivo efficacy of acyl CoA: Diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia.
Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1.
Increased lipid accumulation and insulin resistance in transgenic mice expressing DGAT2 in glycolytic (type II) muscle.
Intestine-targeted DGAT1 inhibition improves obesity and insulin resistance without skin aberrations in mice.
Liver fat accumulation may be dissociated from adiposity gain in ovariectomized rats.
Modeling the mechanism of action of a DGAT1 inhibitor using a causal reasoning platform.
Monoacylglycerol acyltransferase 1 knockdown exacerbates hepatic ischemia-reperfusion injury in mice with hepatic steatosis.
Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1.
Palmitate-induced skeletal muscle insulin resistance does not require NF-kappaB activation.
Paradoxical coupling of triglyceride synthesis and fatty acid oxidation in skeletal muscle overexpressing DGAT1.
Paradoxical increase in TAG and DAG content parallel the insulin sensitizing effect of unilateral DGAT1 overexpression in rat skeletal muscle.
Reduced skeletal muscle oxidative capacity and elevatedceramidebut not diacylglycerol content in severe obesity.
Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation.
Role of adipocyte-derived factors in enhancing insulin signaling in skeletal muscle and white adipose tissue of mice lacking Acyl CoA:diacylglycerol acyltransferase 1.
Storing up trouble: does accumulation of intramyocellular triglyceride protect skeletal muscle from insulin resistance?
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance.
Tangduqing Granules Attenuate Insulin Resistance and Abnormal Lipid Metabolism through the Coordinated Regulation of PPAR? and DGAT2 in Type 2 Diabetic Rats.
Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases.
The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans.
The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment.
The role of acyl-CoA:diacylglycerol acyltransferase (DGAT) in energy metabolism.
Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance.
Whole-body Insulin Resistance in the Absence of Obesity in FVB Mice With Overexpression of Dgat1 in Adipose Tissue.
[Effect of Jinlida on DGAT1 in Skeletal Muscle in Fat-Induced Insulin Resistance ApoE -/- Mice].
Intestinal Failure
Intestinal failure and aberrant lipid metabolism in patients with DGAT1 deficiency.
Lipid Metabolism Disorders
Tangduqing Granules Attenuate Insulin Resistance and Abnormal Lipid Metabolism through the Coordinated Regulation of PPAR? and DGAT2 in Type 2 Diabetic Rats.
Lipodystrophy
Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids.
Liver Cirrhosis
Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis.
Liver Diseases
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease.
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Nonalcoholic fatty liver disease: emerging mechanisms and consequences.
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Recent advances in pharmacotherapy for hypertriglyceridemia.
Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation.
The ménage à trois of autophagy, lipid droplets and liver disease.
Therapeutic Strategies for Metabolic Diseases: Small-Molecule Diacylglycerol Acyltransferase (DGAT) Inhibitors.
TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
Liver Diseases, Alcoholic
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Malnutrition
Genetic variants in DGAT1 cause diverse clinical presentations of malnutrition through a specific molecular mechanism.
Maple Syrup Urine Disease
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
Mastitis
Distinguishing pleiotropy from linked QTL between milk production traits and mastitis resistance in Nordic Holstein cattle.
Significant genetic effects of JAK2 and DGAT1 mutations on milk fat content and mastitis resistance in Holsteins.
Metabolic Diseases
A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism.
ACAT-selective and Nonselective DGAT1 Inhibition: Adrenocortical Effects--A Cross-species Comparison.
Assessment of pharmacokinetic drug-drug interaction between pradigastat and atazanavir or probenecid.
Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.
DGAT1 inhibitors protect pancreatic ?-cells from palmitic acid-induced apoptosis.
Diacylglycerol acyltransferase-1 (DGAT1) inhibition perturbs postprandial gut hormone release.
Identification and validation of a selective small molecule inhibitor targeting the diacylglycerol acyltransferase 2 activity.
Inhibitors of diacylglycerol acyltransferase: a review of 2008 patents.
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH).
Patent landscape for discovery of promising acyltransferase DGAT and MGAT inhibitors.
Pharmacological inhibition of DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia is restricted to the mouse.
Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile.
Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases.
Therapeutic Strategies for Metabolic Diseases: Small-Molecule Diacylglycerol Acyltransferase (DGAT) Inhibitors.
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
Metabolic Syndrome
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor.
Discovery of Orally Active Carboxylic Acid Derivatives of 2-Phenyl-5-trifluoromethyloxazole-4-carboxamide as Potent Diacylglycerol Acyltransferase-1 Inhibitors for the Potential Treatment of Obesity and Diabetes.
Novel acyl coenzyme A: diacylglycerol acyltransferase 1 inhibitors-synthesis and biological activities of N-(substituted heteroaryl)-4-(substituted phenyl)-4-oxobutanamides.
Sesquiterpenoids Isolated from the Flower Buds of Tussilago farfara L. Inhibit Diacylglycerol Acyltransferase.
SIRT6 protects against pathological damage caused by diet-induced obesity.
Muscular Diseases
Inborn errors of cytoplasmic triglyceride metabolism.
Neoplasm Metastasis
Obesity promotes gastric cancer metastasis via diacylglycerol acyltransferase 2-dependent lipid droplets accumulation and redox homeostasis.
Neoplasms
Activation of diacylglycerol O-acyltransferase 1 gene results in increased tumor necrosis factor-alpha gene expression in 3T3-L1 adipocytes.
Cardiac metabolism, inflammation, and peroxisome proliferator-activated receptors modulated by 1,25-dihydroxyvitamin D3 in diabetic rats.
Cell-based assay of MGAT2-driven diacylglycerol synthesis for profiling inhibitors: use of a stable isotope-labeled substrate and high-resolution LC/MS.
Comprehensive Genetic Analysis of DGAT2 Mutations and Gene Expression Patterns in Human Cancers.
DGAT1 Expression Promotes Ovarian Cancer Progression and Is Associated with Poor Prognosis.
DGAT1 Inhibitor Suppresses Prostate Tumor Growth and Migration by Regulating Intracellular Lipids and Non-Centrosomal MTOC Protein GM130.
DGAT1 protects tumor from lipotoxicity, emerging as a promising metabolic target for cancer therapy.
Dgat2 reduces hepatocellular carcinoma malignancy via downregulation of cell cycle-related gene expression.
Direct and maternal n-3 long-chain polyunsaturated fatty acid supplementation improved triglyceridemia and glycemia through the regulation of hepatic and muscle sphingolipid synthesis in offspring hamsters fed a high-fat diet.
Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene.
HDAC Inhibition Modulates Cardiac PPARs and Fatty Acid Metabolism in Diabetic Cardiomyopathy.
Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models.
Intracellular mechanisms underlying lipid accumulation (white opaque substance) in gastric epithelial neoplasms: A pilot study of expression profiles of lipid-metabolism-associated genes.
Loss of ephrin B2 receptor (EPHB2) sets lipid rheostat by regulating proteins DGAT1 and ATGL inducing lipid droplet storage in prostate cancer cells.
Maternal supplementation with n-3 long chain polyunsaturated fatty acids during perinatal period alleviates the metabolic syndrome disturbances in adult hamster pups fed a high-fat diet after weaning.
Mining for novel candidate clock genes in the circadian regulatory network.
Mismatched effects of receptor interacting protein kinase-3 on hepatic steatosis and inflammation in non-alcoholic fatty liver disease.
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Obesity promotes gastric cancer metastasis via diacylglycerol acyltransferase 2-dependent lipid droplets accumulation and redox homeostasis.
Targeting DGAT1 Ameliorates Glioblastoma by Increasing Fat Catabolism and Oxidative Stress.
TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
Up-regulation of DGAT1 in cancer tissues and tumor-infiltrating macrophages influenced survival of patients with gastric cancer.
Nephritis, Interstitial
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
Nephrotic Syndrome
Up-regulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome.
Neuroinflammatory Diseases
Inflammatory, regulatory, and autophagy co-expression modules and hub genes underlie the peripheral immune response to human intracerebral hemorrhage.
Non-alcoholic Fatty Liver Disease
CD36 and DGAT2 facilitate the lipid-lowering effect of chitooligosaccharides via fatty acid intake and triglyceride synthesis signaling.
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease.
Hepatocyte Deletion of Triglyceride-Synthesis Enzyme Acyl CoA: Diacylglycerol Acyltransferase 2 Reduces Steatosis Without Increasing Inflammation or Fibrosis in Mice.
Monoacylglycerol acyltransferase 1 knockdown exacerbates hepatic ischemia-reperfusion injury in mice with hepatic steatosis.
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH).
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Niacin increases diet-induced hepatic steatosis in B6129 mice.
Nonalcoholic fatty liver disease: emerging mechanisms and consequences.
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.
Recent advances in pharmacotherapy for hypertriglyceridemia.
Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation.
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance.
Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis.
The effects of PCB126 on intra-hepatic mechanisms associated with non alcoholic fatty liver disease.
The ménage à trois of autophagy, lipid droplets and liver disease.
TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
Obesity
A novel coenzyme A:diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity.
A novel low systemic diacylglycerol acyltransferase 1 inhibitor, Yhhu2407, improves lipid metabolism.
A simple homogeneous scintillation proximity assay for acyl-coenzyme A:diacylglycerol acyltransferase.
Acyl-CoA:diacylglycerol acyltransferase: Molecular biology, biochemistry and biotechnology.
Adipose tissue fatty acid storage factors: effects of depot, sex and fat cell size.
Altered levels of sirtuin genes (SIRT1, SIRT2, SIRT3 and SIRT6) and their target genes in adipose tissue from individual with obesity.
An N-terminal fragment of mouse DGAT1 binds different acyl-CoAs with varying affinity.
Analysis of energy expenditure at different ambient temperatures in mice lacking DGAT1.
Beyond Triglyceride Synthesis: The Dynamic Functional Roles of MGAT and DGAT Enzymes in Energy Metabolism.
Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets.
Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations.
Deficiency of acyl coenzyme a:diacylglycerol acyltransferase 1 increases leptin sensitivity in murine obesity models.
Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor.
Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.
DGAT and triglyceride synthesis: a new target for obesity treatment?
DGAT inhibitors for obesity.
DGAT1 inhibitors as anti-obesity and anti-diabetic agents.
DGAT2 Inhibition Alters Aspects of Triglyceride Metabolism in Rodents but Not in Non-human Primates.
DGAT: novel therapeutic target for obesity and type 2 diabetes mellitus.
Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial.
Diacylglycerol acyltransferase-1 (DGAT1) inhibition perturbs postprandial gut hormone release.
Diacylglycerol acyltransferase-1 inhibition enhances intestinal fatty acid oxidation and reduces energy intake in rats.
Diacylglycerol acyltransferase-inhibitory compounds from Erythrina senegalensis.
Discovery and optimization of adamantane carboxylic acid derivatives as potent diacylglycerol acyltransferase 1 inhibitors for the potential treatment of obesity and diabetes.
Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor.
Discovery of dimethyl pent-4-ynoic acid derivatives, as potent and orally bioavailable DGAT1 inhibitors that suppress body weight in diet-induced mouse obesity model.
Discovery of novel DGAT1 inhibitors by combination of machine learning methods, pharmacophore model and 3D-QSAR model.
Discovery of Orally Active Carboxylic Acid Derivatives of 2-Phenyl-5-trifluoromethyloxazole-4-carboxamide as Potent Diacylglycerol Acyltransferase-1 Inhibitors for the Potential Treatment of Obesity and Diabetes.
Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.
Dissociation of obesity and impaired glucose disposal in mice overexpressing acyl coenzyme a:diacylglycerol acyltransferase 1 in white adipose tissue.
Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin.
Elevated metabolic rate and skeletal muscle oxidative metabolism contribute to the reduced susceptibility of NF-?B p50 null mice to obesity.
Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: Lessons from mice lacking DGAT1.
Evolutionary view of acyl-CoA diacylglycerol acyltransferase (DGAT), a key enzyme in neutral lipid biosynthesis.
Exploration of pyridine containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors.
Expression of DGAT2 in white adipose tissue is regulated by central leptin action.
Fighting Obesity and Metabolic Disorders with DGAT-1 Inhibitors.
Genetic interaction of DGAT2 and FAAH in the development of human obesity.
Glycerolipid acyltransferases in triglyceride metabolism and energy homeostasis-potential as drug targets.
Hypertrophy and hyperplasia of abdominal adipose tissues in women.
Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes.
Improved glucose tolerance in acyl CoA:diacylglycerol acyltransferase 1-null mice is dependent on diet.
In silico design of diacylglycerol acyltransferase-1 (DGAT1) inhibitors based on SMILES descriptors using Monte-Carlo method.
Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1.
Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1.
Inhibition of diacylglycerol acyltransferase by alkamides isolated from the fruits of Piper longum and Piper nigrum.
Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice.
Inhibitory activity of diacylglycerol acyltransferase by glabrol isolated from the roots of licorice.
Intestine specific expression of acyl CoA:diacylgylcerol acyltransferase 1 (DGAT1) reverses resistance to diet-induced hepatic steatosis and obesity in Dgat1-/- mice.
Intestine-targeted DGAT1 inhibition improves obesity and insulin resistance without skin aberrations in mice.
Isolation of Diacyl Glycerol Acyl Transferase (DGAT) Inhibitors from Pachydictyon coriaceum.
JTP-103237, a novel monoacylglycerol acyltransferase inhibitor, modulates fat absorption and prevents diet-induced obesity.
JTT-553, a novel Acyl CoA:diacylglycerol acyltransferase (DGAT) 1 inhibitor, improves glucose metabolism in diet-induced obesity and genetic T2DM mice.
Knockdown of Acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice.
Modeling the mechanism of action of a DGAT1 inhibitor using a causal reasoning platform.
Mutation screen and association studies in the diacylglycerol O-acyltransferase homolog 2 gene (DGAT2), a positional candidate gene for early onset obesity on chromosome 11q13.
Novel acyl coenzyme A: diacylglycerol acyltransferase 1 inhibitors-synthesis and biological activities of N-(substituted heteroaryl)-4-(substituted phenyl)-4-oxobutanamides.
Obesity promotes gastric cancer metastasis via diacylglycerol acyltransferase 2-dependent lipid droplets accumulation and redox homeostasis.
Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1.
Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat.
Pathogenesis of obesity by food restriction in OLETF rats-increased intestinal monoacylglycerol acyltransferase activities may be a crucial factor.
Pharmacological inhibition of DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia is restricted to the mouse.
Posttranscriptional control of the expression and function of diacylglycerol acyltransferase-1 in mouse adipocytes.
Potential therapeutics for obesity and atherosclerosis: inhibitors of neutral lipid metabolism from microorganisms.
Prolonged silencing of diacylglycerol acyltransferase-1 induces a dedifferentiated phenotype in human liver cells.
Proof of mechanism for the DGAT1 inhibitor AZD7687: Results from a first-time-in-human single dose study.
RNA interference-mediated knockdown of DGAT1 decreases triglyceride content of bovine mammary epithelial cell line.
Sesquiterpenoids Isolated from the Flower Buds of Tussilago farfara L. Inhibit Diacylglycerol Acyltransferase.
Sex and Depot Differences in ex vivo Adipose Tissue Fatty Acid Storage and Glycerol-3-phosphate acyltransferase Activity.
Synthesis and biological evaluation of isoxazole, oxazole, and oxadiazole containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors.
Synthesis and evaluation of cyclohexane carboxylic acid head group containing isoxazole and thiazole analogs as DGAT1 inhibitors.
Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases.
The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment.
Therapeutic Strategies for Metabolic Diseases: Small-Molecule Diacylglycerol Acyltransferase (DGAT) Inhibitors.
Triazolo compounds useful as diacylglycerol acyltransferase1 inhibitor - WO2009126624.
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
Whole-body Insulin Resistance in the Absence of Obesity in FVB Mice With Overexpression of Dgat1 in Adipose Tissue.
Obesity, Abdominal
Adipose tissue diacylglycerol acyltransferase activity and blood lipoprotein triglyceride enrichment in women with abdominal obesity.
Obesity, Morbid
Reduced skeletal muscle oxidative capacity and elevatedceramidebut not diacylglycerol content in severe obesity.
Osteopetrosis
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
Diversity of copy number variation in the worldwide goat population.
Ovarian Neoplasms
DGAT1 Expression Promotes Ovarian Cancer Progression and Is Associated with Poor Prognosis.
Overweight
Altered levels of sirtuin genes (SIRT1, SIRT2, SIRT3 and SIRT6) and their target genes in adipose tissue from individual with obesity.
Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial.
Identification of a botanical inhibitor of intestinal diacylglyceride acyltransferase 1 activity via in vitro screening and a parallel, randomized, blinded, placebo-controlled clinical trial.
Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects.
Pancreatic Neoplasms
Identification of prognostic lipid droplet-associated genes in pancreatic cancer patients via bioinformatics analysis.
Prostatic Neoplasms
DGAT1 Inhibitor Suppresses Prostate Tumor Growth and Migration by Regulating Intracellular Lipids and Non-Centrosomal MTOC Protein GM130.
Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene.
Loss of ephrin B2 receptor (EPHB2) sets lipid rheostat by regulating proteins DGAT1 and ATGL inducing lipid droplet storage in prostate cancer cells.
Positive regulation of prostate cancer cell growth by lipid droplet forming and processing enzymes DGAT1 and ABHD5.
Protein-Losing Enteropathies
Congenital Diarrhea from DGAT1 Mutation Leading to Electrolyte Derangements, Protein-Losing Enteropathy, and Rickets.
Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations.
Reperfusion Injury
Eicosapentaenoic acid attenuates renal lipotoxicity by restoring autophagic flux.
Monoacylglycerol acyltransferase 1 knockdown exacerbates hepatic ischemia-reperfusion injury in mice with hepatic steatosis.
Rickets
Congenital Diarrhea from DGAT1 Mutation Leading to Electrolyte Derangements, Protein-Losing Enteropathy, and Rickets.
Starvation
Changes in the photosynthetic apparatus and lipid droplet formation in Chlamydomonas reinhardtii under iron deficiency.
Cloning and molecular characterization of a novel acyl-CoA: diacylglycerol acyltransferase 1-like gene (PtDGAT1) from the diatom Phaeodactylum tricornutum.
Effect of Single and Combined Expression of Lysophosphatidic Acid Acyltransferase, Glycerol-3-Phosphate Acyltransferase, and Diacylglycerol Acyltransferase on Lipid Accumulation and Composition in Neochloris oleoabundans.
Identification and characterization of an efficient acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) gene from the microalga Chlorella ellipsoidea.
PHA-4/FoxA senses nucleolar stress to regulate lipid accumulation in Caenorhabditis elegans.
Recycling the Danger via Lipid Droplet Biogenesis After Autophagy.
The activities of lipoprotein lipase and of enzymes involved in triacylglycerol synthesis in rat adipose tissue. Effects of starvation, dietary modification and of corticotropin injection.
The diacylglycerol acyltransferase Rv3371 of Mycobacterium tuberculosis is required for growth arrest and involved in stress-induced cell wall alterations.
Three acyltransferases and a nitrogen responsive regulator are implicated in nitrogen starvation-induced triacylglycerol accumulation in Chlamydomonas.
Stomach Neoplasms
Obesity promotes gastric cancer metastasis via diacylglycerol acyltransferase 2-dependent lipid droplets accumulation and redox homeostasis.
Up-regulation of DGAT1 in cancer tissues and tumor-infiltrating macrophages influenced survival of patients with gastric cancer.
Syndactyly
A Review of Selected Genes with Known Effects on Performance and Health of Cattle.
Toxoplasmosis
Novel Approaches To Kill Toxoplasma gondii by Exploiting the Uncontrolled Uptake of Unsaturated Fatty Acids and Vulnerability to Lipid Storage Inhibition of the Parasite.
triacylglycerol lipase deficiency
Leptin modulates the effects of acyl CoA:diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands.
Tuberculosis
Comparative genomics of the dormancy regulons in mycobacteria.
Identification of a diacylglycerol acyltransferase gene involved in accumulation of triacylglycerol in Mycobacterium tuberculosis under stress.
The diacylglycerol acyltransferase Rv3371 of Mycobacterium tuberculosis is required for growth arrest and involved in stress-induced cell wall alterations.
The Mycobacterium tuberculosis Ag85A is a novel diacylglycerol acyltransferase involved in lipid body formation.